Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 16/20 | 1.00 |
| ▸ | GSTM2 | P28161 | 16/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296944 | 0.87 | GSTP1 (0.77) | GSTP1GSTM2IDO1CASP6 | |
| SCHEMBL298137 | 0.84 | GSTP1 (0.72) | GSTP1GSTM2IDO1 | |
| SCHEMBL13997681 | 0.80 | GSTP1 (0.66) | GSTP1GSTM2 | |
| SCHEMBL6836307 | 0.79 | GSTP1 (1.00) | GSTP1GSTM2MEN1HTTRECQL | |
| SCHEMBL300204 | 0.78 | GSTP1 (0.82) | GSTP1GSTM2 | |
| SCHEMBL18878890 | 0.78 | GSTP1 (0.77) | GSTP1GSTM2MEN1HTTRECQL | |
| SCHEMBL3502370 | 0.77 | GSTP1 (0.74) | GSTP1GSTM2ALDH1A1MAPT | |
| SCHEMBL6049348 | 0.76 | GSTP1 (0.74) | GSTP1GSTM2IDO1 | |
| SCHEMBL7052057 | 0.75 | GSTM2 (0.66) | GSTP1GSTM2MEN1HTTRECQL | |
| SCHEMBL3712753 | 0.75 | GSTP1 (0.65) | GSTP1GSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | claimed |
| EP-2427442-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | claimed |
| WO-2010128156-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-8865901-B2 | Gain-of-function Bcl-2 inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865901-B2 | Gain-of-function Bcl-2 inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2427442-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011041737-A2 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041731-A2 | METHOD OF INHIBITING BCL-2-RELATED SURVIVAL PROTEINS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010128156-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | GSTP1 719/4885GSTM2 266/4885MEN1 3416/4885 |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TENT4B, IRF3, MAVS | GSTP1 1679/4885GSTM2 2265/4885MEN1 4597/4885 |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | GSTP1 2321/4885GSTM2 1424/4885MEN1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.